Streetbeat News

Analyst Ratings

ACN

BMO Capital analyst Keith Bachman has maintained a 'Market Perform' rating on Accenture (NYSE:ACN) but lowered the price target from $360 to $350.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 1:06 pm

EDIT

Stifel has upgraded Editas Medicine from Hold to Buy and raised its price target from $9 to $17, leading to a rise in the company's shares.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 1:03 pm

BMI

In the last quarter, Badger Meter (NYSE:BMI) received one bullish and three indifferent analyst ratings. The average 12-month price target for the company, according to four analysts, is $149.25, an increase of 11.11% from the previous average of $134.33.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 1:00 pm

SNPS

Synopsys (NASDAQ:SNPS) has received 10 analyst ratings in the last quarter, all of which are bullish to some extent. The average price target is $501.1, indicating an upside from the current price of $467.5999. This average has increased by 6.58% from the previous average price target of $470.17.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 1:00 pm

DXCM

Analysts have provided various ratings for DexCom (NASDAQ:DXCM) within the last quarter, with a total of 5 bullish, 3 somewhat bullish, and 2 indifferent ratings. The average price target given by these analysts is $140.2, which is higher than DexCom's current price of $97.05. However, this average has decreased by 2.91% from the previous average price target of $144.40.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 1:00 pm

AMH

Analysts have given American Homes 4 Rent (NYSE:AMH) mostly bullish ratings in the last quarter, with an average 12-month price target of $39.0, up 7.08% from the previous average of $36.42. In the last 3 months, 7 analysts have offered 12-month price targets for the company.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 1:00 pm

PODD

Over the past 3 months, 14 analysts have published their opinion on Insulet (NASDAQ:PODD) stock. The company has an average price target of $265.57, a 17.3% decrease from the previous average price target of $321.14. The ratings include 2 bullish, 5 somewhat bullish, and 7 indifferent.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 1:00 pm

ABBV

Over the past three months, four analysts have published their opinions on AbbVie (NYSE:ABBV) stock, with one being bullish and three somewhat bullish. The average 12-month price target for AbbVie is $174.0, with a high of $182.00 and a low of $167.00. This average price target has increased by 0.87% over the past month.

Portfolio Pulse from Benzinga Insights

September 29, 2023 | 1:00 pm

USAC

Mizuho analyst Gabriel Moreen has downgraded USA Compression Partners (NYSE:USAC) from Neutral to Underperform and set a price target of $22.

Portfolio Pulse from Benzinga Newsdesk

September 29, 2023 | 12:58 pm

GPCR

NVO

Structure Therapeutics Inc released results from the Phase 1b study of GSBR-1290, showing significant weight loss in overweight or obese individuals. The company also announced a private placement of 21.6 million shares and 2.4 million non-voting shares at $12.49 per share, raising $300 million. The funds are expected to extend the cash runway through 2026. GPCR shares are up 68.1% in premarket trading.

Portfolio Pulse from Vandana Singh

September 29, 2023 | 12:55 pm